Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-06 02:02 UTC

BIOMED PULSE

Sunday, September 6, 2026 — Daily Edition

⚡ TL;DR

The Bundibugyo virus disease (BVD) Ebola outbreak in the Democratic Republic of the Congo has now spread to 60 health zones across six provinces, making it the largest Ebola outbreak ever recorded in the DRC, with sustained transmission showing no sign of peaking. [1] Separately, a new Salmonella outbreak tied to Metabolic Meals home delivery food has been identified across 10 states, adding to an already crowded foodborne illness landscape this season. [2] Mood: grave on hemorrhagic fever; cautiously watchful on food safety.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) — DRC AND UGANDA: LARGEST EBOLA OUTBREAK ON RECORD

  • As of August 28, 2026, the BVD outbreak had spread from 54 to 60 health zones, now touching six of 26 DRC provinces: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo. [1]
  • The most recent WHO Disease Outbreak News (DON-616, published August 28) notes six additional health zones reported new cases since the August 14 update (DON-615). [1] [3]
  • DON-615 described the outbreak as "the largest Ebola outbreak ever reported in the DRC and expanding faster than any previous Ebola outbreak," with sustained transmission in urban, peri-urban, and rural settings simultaneously. [3]
  • As of July 15, 2026 (DON-613), cumulative confirmed cases had reached 2,124 with 828 deaths; case counts have climbed steeply in every subsequent update. [4]
  • Cross-border spread to Uganda was confirmed when DRC and Uganda jointly declared the outbreak on May 15, 2026, following confirmation of Bundibugyo virus (a rare Ebola species first identified in Uganda in 2007) by the INRB laboratory in Kinshasa. [5] [6]
  • CDC mobilized its international Ebola response in mid-May 2026 and launched enhanced airport screening first at Washington-Dulles International Airport, then expanded to Atlanta Hartsfield-Jackson. [7] [8]

SALMONELLA — METABOLIC MEALS HOME DELIVERY: NEW INVESTIGATION

  • CDC posted a new investigation notice on September 5, 2026: 16 people in 10 states have fallen ill with the same Salmonella strain linked to Metabolic Meals home delivery food products. [2]
  • This adds to a multi-outbreak Salmonella burden in 2026 that has also included backyard poultry (34 cases across 13 states as of April 2026), jalapeños (August 2026), and alfalfa sprouts (August 2026, with dual E. coli and Salmonella contamination). [9] [10]
  • A previously reported Salmonella outbreak linked to recalled eggs reached 95 cases in 14 states as of August 28, 2026; consumers in affected states should discard recalled egg products.

CYCLOSPORA — TACO BELL SHREDDED LETTUCE: ONGOING

  • As of July 24, 2026, the Cyclospora outbreak linked to shredded iceberg lettuce at Taco Bell locations had expanded to four new states beyond the original five; the initial July 17 alert cited 1,644 sick individuals across five states.
  • The parasite Cyclospora cayetanensis causes prolonged watery diarrhea; the implicated vehicle is shredded iceberg lettuce served at specific Taco Bell locations — do not eat this product in affected areas.

HANTAVIRUS — M/V HONDIUS CRUISE SHIP: MONITORING CONTINUES

  • The Andes hantavirus (ANDV) cluster linked to the M/V Hondius cruise ship has been the subject of five WHO Disease Outbreak News reports since May 2, 2026; the fifth DON (DON-611, July 2, 2026) documented continued case follow-up across multiple countries.
  • CDC provided response transcripts through June 24, 2026, confirming ongoing monitoring; Andes hantavirus is notable as the only hantavirus strain with documented person-to-person transmission.
  • The outbreak began when passengers aboard the 147-person ship developed severe respiratory illness (hantavirus pulmonary syndrome); the initial WHO notification on May 2, 2026 identified two laboratory-confirmed cases and five suspected cases.

NIPAH VIRUS — KERALA, INDIA: SPORADIC CASE

  • WHO DON-609 (June 25, 2026) reported one laboratory-confirmed Nipah virus (NiV) infection in an adult male in Kozhikode district, Kerala State, India; symptom onset was May 30, 2026, with hospitalization on June 10.
  • The case presented with neurological symptoms; Kerala has experienced repeated Nipah spillover events since 2018, with Pteropus fruit bats serving as the reservoir host.

WEST NILE VIRUS — UNITED STATES: EARLY SEASON SURGE

  • CDC flagged on July 1, 2026 that the 2026 West Nile virus season was arriving earlier than usual with record case counts, urging the public to use mosquito repellent through the holiday weekend and beyond.

MEASLES — BANGLADESH: NATIONWIDE SPREAD

  • WHO DON-598 (April 23, 2026) reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts in all eight divisions of Bangladesh, signaling a major nationwide resurgence.
  • This follows WHO and CDC data from late 2024 showing measles infected 10.3 million people globally in 2023.

AVIAN INFLUENZA H9N2 — ITALY: IMPORTED HUMAN CASE

  • WHO DON-597 (April 10, 2026) reported a human case of influenza A(H9N2) in an adult male returning to Italy from Senegal, confirmed by next-generation sequencing; H9N2 is a low-pathogenicity avian influenza strain but is monitored for pandemic potential.

DRUG-RESISTANT BACTERIA — UNITED STATES: SHARP RISE

  • A CDC report published September 23, 2025 found a dramatic increase in a dangerous type of drug-resistant bacteria in healthcare settings, underscoring the continuing antimicrobial resistance threat.
  • Congenital syphilis in the U.S. increased for the 12th consecutive year in 2024, per CDC STI data released September 24, 2025, adding to the antimicrobial-resistant STI burden.

🧬 LONGEVITY & AGING

TESTOSTERONE, LONGEVITY, AND REPRODUCTIVE FITNESS: A TRADE-OFF REVEALED

  • A Mendelian randomization study published August 17, 2026 in Aging Male (Jiesisibieke and Schooling) used genetic proxies to causally test whether testosterone confers longevity benefits or comes at a reproductive fitness cost, finding evidence of genuine biological trade-offs rather than simple correlation.
  • An international expert consensus published August 26, 2026 in Aging Male (David, Burte, Byrne, Hackett, Jones, Khera, Morgentaler, et al.) produced updated primary-care guidance on managing testosterone deficiency, noting its links to cardiometabolic risk, frailty, and quality of life in aging men.

SENESCENT CELLS AND DISC DEGENERATION: NOVEL DELIVERY APPROACH

  • A Biomaterials study (published July 14, 2026; Shi, Yang, Wu et al.) engineered extracellular vesicles loaded with senescence-targeting apoptotic cargo inside injectable hydrogel microspheres to combat nucleus pulposus cell ferroptosis (iron-driven cell death) in intervertebral disc degeneration — a target increasingly linked to spinal aging.

SENESCENCE IN OSTEOARTHRITIS: DUAL ANTIOXIDANT-EPIGENETIC STRATEGY

  • A Bioactive Materials paper (July 31, 2026; An, Cai, Wu et al.) showed that combining antioxidant therapy with epigenetic reprogramming disrupted the self-perpetuating senescence cycle in osteoarthritis cartilage, pointing toward combination senolytics as a viable approach.

METFORMIN DELIVERY TO CARTILAGE: TETRAHEDRAL DNA NANOPARTICLE

  • A Biomaterials study (July 6, 2026; Han, Jiang, Deng et al.) engineered a chondrocyte-targeting tetrahedral DNA nanoparticle to deliver metformin directly into joint cartilage, improving osteoarthritis outcomes in preclinical models and suggesting repurposing of the widely used diabetes drug for joint aging.

EGFR LOSS IN AGING BONE: FRACTURE HEALING IMPAIRED

  • A Bioactive Materials paper (August 4, 2026; Hu, Wang, Chen et al.) found that loss of EGFR (epidermal growth factor receptor) activity in skeletal stem and progenitor cells is mechanistically associated with impaired fracture healing in aged mice, identifying EGFR signaling as a potential therapeutic target in geriatric fracture care.

ABCA1 AND CHOLESTEROL IN AGE-RELATED BONE DEFECTS: mRNA LNP STRATEGY

  • A Bioactive Materials study (August 20, 2026; Cheng, Xi, Ni et al.) used a dual-targeting mRNA lipid nanoparticle to restore ABCA1-dependent cholesterol homeostasis in bone tissue, promoting repair of age-related bone defects in animal models — an application of the mRNA-LNP platform beyond vaccines.

HEAT TOLERANCE, AGING, AND CLIMATE: GLOBAL PROJECTION

  • A Lancet Planetary Health modeling study (Kong, Vecellio, Huber, Bendavid, Kenney et al.) projected that warming climate combined with global population aging will cause a growing proportion of older adults worldwide to exceed safe human heat tolerance thresholds, with older people physiologically less able to thermoregulate in extreme heat.

DEPRESCRIBING IN OLDER ADULTS: CALL FOR RATIONALE-FIRST TRIAL DESIGN

  • Two linked Lancet Healthy Longevity commentaries (Hwang, Boockvar, Steinman; and Van der Linden) argue that deprescribing clinical trials — reducing medications in older patients — must begin with a mechanistic rationale before choosing a trial design, as polypharmacy remains a leading driver of adverse drug events in aging populations.

ANESTHESIA FOR HIP FRACTURE SURGERY IN OLDER PATIENTS: RCT FINDINGS

  • A multicenter randomized clinical trial published in Lancet Healthy Longevity (Kowark, Schoenen, Schmidt et al., Germany) compared spinal versus general anesthesia for hip fracture surgery in older patients, directly testing which approach yields fewer serious complications in a fragile population.
  • An accompanying editorial by Moppett and Shelton in Lancet Healthy Longevity framed the question as one of the most consequential unanswered issues in geriatric surgical care.

DEMENTIA AND CANCER INCIDENCE: SEX-SPECIFIC ECOLOGICAL ANALYSIS

  • A Future Science OA study (September 4, 2026; You, Chang, Coventry, Sahay, Henneberg) conducted a cross-country ecological analysis finding sex-specific associations between cancer incidence rates and dementia incidence, suggesting shared biological pathways — such as immune surveillance — may modulate both conditions differently by sex.

CALORIE RESTRICTION AND LIFESPAN: SCALLOP TRANSCRIPTOMICS

  • A Comparative Biochemistry and Physiology study (August 10, 2026; Zhao, Zhang, Liu et al.) compared two Argopecten scallop species with distinct natural lifespans and found species-specific transcriptomic adaptive strategies to calorie restriction, offering an invertebrate model for dissecting the longevity-calorie restriction axis.

UROLITHIN A SUPPLEMENTATION IN OLDER ADULTS: GLUCOSE METABOLISM TRIAL ACTIVE

  • ClinicalTrials.gov NCT06274749 is a randomized triple-masked controlled trial studying the effects of Urolithin A (UA) supplementation on glucose metabolism in healthy adults aged 55 and older; UA is a gut-derived mitophagy activator shown to improve mitochondrial function and muscle endurance in prior human studies.

NICOTINAMIDE RIBOSIDE AND METABOLIC RATE: ACTIVE TRIAL

  • NCT06044935 on ClinicalTrials.gov is testing how nicotinamide riboside (NR), an NAD+ precursor, affects ketosis, fat oxidation, and metabolic rate, with relevance to fatty liver disease affecting at least 30 percent of Americans; the trial uses a low-carbohydrate diet co-intervention.

💊 NEW CURES & APPROVALS

KRAZATI (ADAGRASIB) — BRISTOL-MYERS SQUIBB: SUPPLEMENTAL APPROVAL

  • openFDA records a supplemental approval (SUPPL AP) for KRAZATI (adagrasib), sponsor Bristol-Myers Squibb (Bristol), NDA 216340; adagrasib is a KRASG12C inhibitor used in KRAS-mutant non-small cell lung cancer and colorectal cancer, with the supplemental action potentially expanding its labeled use.

BYOOVIZ (RANIBIZUMAB-NUNA) — SAMSUNG BIOEPIS: SUPPLEMENTAL APPROVAL

  • openFDA records a supplemental approval for BYOOVIZ (ranibizumab-nuna), a VEGF-A-targeting biosimilar to Lucentis, sponsor Samsung Bioepis Co. Ltd., BLA 761202; indicated for neovascular age-related macular degeneration (wet AMD) and other retinal conditions — a disease of aging.

CIBINQO (ABROCITINIB) — PFIZER: SUPPLEMENTAL APPROVAL

  • openFDA records a supplemental approval for CIBINQO (abrocitinib), a JAK1 inhibitor for moderate-to-severe atopic dermatitis, sponsor Pfizer, NDA 213871; JAK inhibitors in this class are also under investigation for inflammatory aging-related conditions.

FYARRO (SIROLIMUS) — AADI: SUPPLEMENTAL APPROVAL

  • openFDA records a supplemental approval for FYARRO (sirolimus protein-bound particles), sponsor AADI, NDA 213312; sirolimus (rapamycin) is an mTOR inhibitor and one of the most-studied longevity compounds in preclinical models — its approved oncology use in malignant perivascular epithelioid cell tumors (PEComa) continues to expand.

SHEUR (ELAGOLIX / ESTRADIOL / NORETHINDRONE ACETATE) — TEVA PHARMA: ORIGINAL TENTATIVE APPROVAL

  • openFDA records an original tentative approval (ORIG TA) for SHEUR, a combination of elagolix, estradiol, and norethindrone acetate, sponsor Teva Pharmaceuticals, ANDA 217650; this hormone-modulating regimen is used to manage symptoms of endometriosis in premenopausal women.

DAPAGLIFLOZIN — AJANTA PHARMA: SUPPLEMENTAL APPROVAL

  • openFDA records a supplemental approval for dapagliflozin, an SGLT2 inhibitor (generic), sponsor Ajanta Pharma Ltd., ANDA 211482; SGLT2 inhibitors have demonstrated mortality and heart failure benefits and are under active investigation for longevity-adjacent applications including kidney protection.

NEVIRAPINE — MYLAN: SUPPLEMENTAL APPROVAL

  • openFDA records a supplemental approval for nevirapine (generic), a non-nucleoside reverse transcriptase inhibitor for HIV, sponsor Mylan, ANDA 205651; relevant in the context of ongoing global HIV treatment access efforts.

🧪 CLINICAL TRIALS

KARXT FOR ALZHEIMER'S PSYCHOSIS — PHASE 3 ADEPT-2 TRIAL: ACTIVE

  • NCT06126224 (ADEPT-2) is a Phase 3 randomized double-blind placebo-controlled trial evaluating KarXT (xanomeline-trospium), a muscarinic M1/M4 receptor agonist, for psychosis associated with Alzheimer's disease in adults aged 55 to 90; the primary outcome targets moderate-to-severe AD with moderate-to-severe psychosis.
  • KarXT (brand name Cobenfy) received FDA approval in late 2024 for schizophrenia; ADEPT-2 tests whether the same cholinergic mechanism addresses neuropsychiatric symptoms in the largest aging-associated dementia.

TILREKIMAB FOR ATOPIC DERMATITIS — STUDY ACTIVE

  • NCT07765888 is evaluating tilrekimig (tilrekimab), an anti-IL-31 receptor antibody candidate, in adults and adolescents with moderate-to-severe atopic dermatitis used in combination with topical corticosteroids; IL-31 drives the itch-scratch cycle that severely impairs quality of life in aging skin.

VENETOCLAX PLUS ASTX727 FOR ELDERLY AML PATIENTS — PHASE 2 ACTIVE

  • NCT04746235 is a Phase 2 trial studying venetoclax (BCL-2 inhibitor) combined with ASTX727 (cedazuridine-decitabine, an oral hypomethylating agent) in relapsed/refractory or newly diagnosed elderly AML patients not eligible for intensive chemotherapy — a population defined explicitly by age and functional status.

FOSTAMATINIB IN LUNG TRANSPLANT PATIENTS — SIMILAR TRIAL

  • NCT06948097 (SIMILAR trial) is evaluating the Syk kinase inhibitor fostamatinib for safety and tolerability in lung transplant recipients who have developed donor-specific antibodies (DSA), a leading driver of chronic allograft rejection and premature death in transplant recipients — a critical aging-adjacent intervention.

UROLITHIN A FOR GLUCOSE METABOLISM IN ADULTS 55-PLUS — ACTIVE RCT

  • NCT06274749 is a randomized triple-masked controlled trial of Urolithin A supplementation on pancreatic insulin secretion and blood glucose control in healthy adults 55 years and older, targeting the mitophagy pathway as a metabolic aging intervention.

NICOTINAMIDE RIBOSIDE, KETOSIS, AND FAT OXIDATION — ACTIVE TRIAL

  • NCT06044935 tests whether nicotinamide riboside (NR), a vitamin B3 derivative that raises cellular NAD+ levels, improves fat oxidation and metabolic rate in adults with fatty liver, pairing the supplement with a low-carbohydrate dietary intervention.

TAPISTRY PLATFORM STUDY — PRECISION IMMUNO-ONCOLOGY: ONGOING

  • NCT04589845 (TAPISTRY) is a global Phase 2 multicenter open-label multi-cohort platform trial evaluating targeted therapies and immunotherapy in patients with unresectable, locally advanced, or metastatic solid tumors identified by tumor-agnostic genomic profiling — relevant to cancer as a dominant cause of non-aging-related mortality in older adults.

📢 PUBLIC HEALTH

SALMONELLA OUTBREAK — METABOLIC MEALS HOME DELIVERY: CONSUMER ALERT

  • CDC posted September 5, 2026: 16 people in 10 states have gotten sick from the same Salmonella strain linked to Metabolic Meals home delivery food; consumers who have received these products should not eat them and should watch for symptoms including diarrhea, fever, and stomach cramps. [2]

ALFALFA SPROUTS — DUAL E. COLI AND SALMONELLA OUTBREAK: RECALL IN EFFECT

  • CDC warned August 21, 2026 of a multistate outbreak of both Salmonella and E. coli O157:H7 infections linked to recalled alfalfa sprout products; consumers should discard any recalled alfalfa sprouts immediately.

LISTERIA — PREPARED MEALS OUTBREAK: ONGOING WITH ADDITIONAL DEATH

  • Multiple CDC updates through 2025 and into 2026 on a Listeria monocytogenes outbreak linked to prepared meals reported additional illnesses and at least one more death as of the most recent update; CDC urges consumers to check refrigerators and freezers for any recalled prepared meal products.

EBOLA AIRPORT SCREENING — WASHINGTON-DULLES AND ATLANTA: ENHANCED MEASURES ACTIVE

  • CDC expanded enhanced Ebola screening from Washington-Dulles International Airport (May 21, 2026) to Atlanta Hartsfield-Jackson International Airport (May 23, 2026) for travelers arriving from DRC and Uganda during the Bundibugyo virus outbreak. [7] [8]

CDC BIOSURVEILLANCE — TRAVELER GENOMIC SURVEILLANCE: ONE MILLION PARTICIPANTS

  • CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 30, 2026, strengthening the nation's ability to detect emerging pathogens crossing borders.

TIMOR-LESTE — MALARIA-FREE CERTIFICATION: PUBLIC HEALTH WIN

  • WHO certified Timor-Leste as malaria-free on July 23-24, 2025, recognizing the country's concerted nationwide response begun shortly after independence in 2002 — a model for elimination in resource-limited settings.

YELLOW FEVER — GLOBAL ACTIVITY IN 2026: SURVEILLANCE NOTE

  • WHO DON-610 (June 24, 2026) reported that from January 1 to May 26, 2026, six countries in the Americas reported a total of 79 human yellow fever infections, a continuation of elevated transmission from 2025; travelers to endemic areas should ensure vaccination.

This briefing is informational only and does not constitute medical advice. Consult a licensed healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Certain Metabolic Meals home delivery foods reported in ongoin… — CDC Newsroom
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Ebola disease caused by Bundibugyo virus – Democratic Republic… — WHO Disease Outbreak News
  7. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  8. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  9. CDC announces <em>Salmonella</em> outbreak in 13 states linked… — CDC Newsroom
  10. CDC warns of <em>Salmonella</em> outbreak linked to jalapeños — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260906-02-v67 · 2026-09-06 02:02 UTC · pulse.uzylab.com

Read next